

São Paulo - Brazil

Is a complete viral load suppression required to reduce the risk of cytomegalovirus recurrence in kidney transplant recipients using the preemptive strategy?

Hospital do Rim – Fundação Oswaldo Ramos; Nephrology Division – Universidade Federal de São Paulo

PURPOSE

To evaluate the impact of two viral load (VL) thresholds for withdrawing antiviral treatment on the cytomegalovirus (CMV) recurrence in kidney transplant recipients (KTRs) following a preemptive strategy.

METHODS

Single-center cohort study at Hospital do Rim (São Paulo -Brazil) **Quasi-experiment before-and-after**




São Paulo - Brazil



1. CMV viremia monitored weekly for three months post- transplant;

Antiviral treatment initiated upon asymptomatic viremia 2. exceeding 5,000 IU/mL or symptomatic CMV;

3. Follow-up: 1-yr post-transplant.





CMV recurrence at preemptive strategy

Arthur Heinz Miehrig; Mônica Rika Nakamura; Pedro Oliveira; Renato Foresto; Helio Tedesco-Silva; ; Lúcio Requião-Moura; José Medina Pestana

RESULTS All patients received a single 3.0 mg/kg dose of rATG for induction and were maintained on a regimen of tacrolimus (99.5%), prednisone (100%), and mycophenolate (100%)				Time between transplant and 1 st CMV-event	Undetectable VL (N= 664)	VL < 200 IU/ml (N=384)	p	
					27 days	23 days	< 0.001	
Variables	Undetectable VL (N= 664)	VL < 200 IU/ml (N=384)	р	Time between 1 st CMV-event and recurrence	44 days	37 days	0.08	
Recipient age, years	48	40	0.072					
Recipient ethnicity (White), %	55.7	41.9	< 0.001	Time for achie	eving the preem	ptive treatment	goal	
Donor age, years	52	54	0.003	150-	8 P		8	
Deceased donor, %	90.2	94.3	0.022		etectable VL			
Cerebrovascular brain death , % 68.1		71.3	0.013	140	_ < 200 IU/ml			
Hypertension - donors, %	40.7	50.8	0.001	الالا چ 120-				
KDPI, median of %	76	80	0.062					
Primary Outcome 100- 90- 90- 80- 70- 70- p=0.26 50- 50- 40- 40-	VL			junde	p<0.001	VL < 200 IU/ml 22 (20-28)		
30-		p=0.24		CONCLUSIONS				


RESULTS All patients received a single 3.0 mg/kg dose of rATG for induction and were maintained on a regimen of tacrolimus (99.5%), prednisone (100%), and mycophenolate (100%)						Undetectable VL (N= 664)	VL < 200 IU/ml (N=384)	p	
					Time between transplant and 1 st CMV-event	27 days	23 days	<0.001	
Variabl	es	Undetectable VL (N= 664)	VL < 200 IU/ml (N=384)	р	Time between 1 st CMV-event and recurrence	44 days	37 days	0.08	
Recipie	nt age, years	48	40	0.072					
Recipie	Recipient ethnicity (White), % 55.2		41.9	< 0.001	Time for achie	Time for achieving the preemptive treatment goa			
Donor a	ige, years	52	54	0.003	150-	0 1 1 1 1		0	
Decease	ed donor, %	90.2	94.3	0.022		etectable VL			
Cerebrovascular brain death , %		68.1	71.3	0.013	I∓0 ■ VI <	< 200 IU/ml			
Hyperte	ension - donors, %	40.7	50.8	0.001	130- (i) 130-				
KDPI, m	nedian of %	76	80	0.062	(ship) - 110-				
100- 90- 80- 70- (%) 60- 50- 40-	Undetectable V VL<200 IU/ml p=0.26 50.5								
30-	30- p=0.24				CONCLUSIONS				





Adjusting preemptive strategy thresholds to allow a low but detectable VL for withdrawing the antiviral therapy significantly shortened treatment duration without increasing CMV recurrence risk, thereby offering a potentially optimized approach for managing CMV in KTRs.





monica.nakamura@hrim.com.br